Sobi once again in the Dow Jones Sustainability Indices
Sobi has once again qualified as a constituent of the Dow Jones Sustainability Indices (DJSI). Sobi joins the DJSI Europe and stands among the ten companies within the Pharmaceuticals, Biotechnology & Life Sciences industry grouping. In total, the DJSI Europe for 2023 includes 150 companies across various industries.
"Being included in the Dow Jones Sustainability Indices again is further recognition of Sobi’s progress as we continue on our sustainability journey,” says Cecilia Nord, Global Head of Sustainability at Sobi. “This achievement is made possible through strong collaboration across various functions. Sustainability is increasingly important to our stakeholders, and we are committed to integrating sustainable business practices into our ways of working to ensure continued progress in the future."
The DJSI is powered by the S&P Global Corporate Sustainability Assessment (CSA), which evaluates all aspects contributing to a company’s sustainability performance. The top performers in each of the 62 industries considered become members of one or several DJSI indices. Sobi has been taking part in this assessment since 2020.
The full results and list of DJSI constituents are available on the S&P Global website.
We provide access to innovative treatments that transform life for people.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Every day, we work actively to find better ways to understand and meet patient needs.
Find out more about our business and financial performance.
Here we present current and past media releases, images and videos.
- About
- Therapeutic areas
- Medicines
- Stories
- Sustainability
- Careers
- Investors
- Media
- English
- Swedish